Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:3... ( NEW YORK Aug. 7 /- Keryx Biopharm...)

HOME >> BIOLOGY >> TECHNOLOGY

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT

Date:8/7/2008

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, August 11, 2008 at 8:30 a.m. EDT to discuss the second quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-719-9788 (U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulat
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:11/6/2009)...whead’s 2010 Personalized Medicine Partnersh...uary 22-24, 2010 in Philadelphia, has been announc... key issues in forming partnerships and engage the... Minneapolis, MN (PRWEB) Novemb...10 Personalized Medicine Partnerships Conference ,...

(Date:11/5/2009)...-- The endangered black-footed ferrets inhabit pra...ivore feeds on prairie dogs. The prairie dogs ar...lation die-offs in towns occur. The U.S. Fish &am... breeding program and has been releasing trained, .... Unfortunately, plague can sweep through and dec...

(Date:11/5/2009)...ire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KO...r processing and storing adult stem cells, today r...10. ,, For the quarter ended September 30, 2009... 15 percent increase over revenues of $4.5 million... the key contributors to the growth in revenues in...

(Date:11/5/2009)...tCall/ -- BioSpecifics Technologies Corp. (Nasdaq:...irst-in-class collagenase-based products, today an...r ended September 30, 2009. ,, "We were extrem...,s Arthritis Advisory Committee unanimously recomm...TM) for the treatment of Dupuytren,s disease, and ...

Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2 Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3 Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8 BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2 BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3 BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4 BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5

[0] Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference [0] Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret [0] ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line [0] BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results

...12 New Delhi based Mayuka Labs,Private Limited ha...amp;,development facility from the department of s... ministry of science and technology, Government of...ound the clock at its R&D and Pilot,unit at Na...its first year of,operations. The company has file...

...w white papers detailing sterility testing essenti...test ( www.microtestlabs.com ). The white papers,...cturers and one which is specialized for pharmaceu... and problems associated with sterility testing an...r medical device manufacturers, sterility testing ...

...ista Therapeutics, Inc. (NYSE Alternext US : SY...dy, a Phase 2 double-blind, placebo-controlled, ra...m. The study is designed to measure the effect of ...chronic systolic heart failure. In addition, the C...EAK ( B eginning a R andomized E valuation of th...

Other Biology Technology:Mayuka Labs R&D Centre Gets DSIR Recognition 2 Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2 Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2 Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3 Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4

Mayuka Labs R&D Centre Gets DSIR Recognition Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

(Date:11/8/2009)...due University have discovered a new approach for ...ries using nano-spheres that could be injected int...thetic "copolymer micelles" are drug-delivery sphe...0 times smaller than the diameter of a red blood c...iver drugs for cancer treatment and other therapie...

(Date:11/8/2009)...H INTELLECTUAL DISABILITIES: AN OPPORTUNITY FOR HE...olving adults with intellectual disabilities found...nowledge after taking a semi-weekly class for four...cepted term for mental retardation, have slightly ...reventable chronic diseases compared to the genera...

(Date:11/6/2009)...h of the publication of On the Origin of Species, ...S) is publishing open access two peer-reviewed art...ts into evolution. , The two articles are by Kevi..., and James T. Costa of Western Carolina Universit...in," appeared in the October issue of the AIBS jou...

Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2 Findings show nanomedicine promising for treating spinal cord injuries 3 Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2 Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 1 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 2 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 3 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 4 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 5 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 6 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 7 Antibiotic Resistance Still a Major Public Health Threat 60427 1 Antibiotic Resistance Still a Major Public Health Threat 60427 2 Antibiotic Resistance Still a Major Public Health Threat 60427 3 Antibiotic Resistance Still a Major Public Health Threat 60427 4 Asians Seem to Suffer Less During Childbirth 60423 1 Asians Seem to Suffer Less During Childbirth 60423 2

[1] Findings show nanomedicine promising for treating spinal cord injuries [0] Indiana U. at APHA: Studies about health education for people with ID, stability balls at work [0] AIBS publishes Darwin articles open access

... in humans, scientists have found early indicators...-related injuries caused by repetitive motion. , ...on and prevention of debilitating conditions such ... new study from Temple University senior researche...ent, Stephen Carp, in the March issue of Clinical ...

... the Ludwig Institute for Cancer Research (LICR) a...School of Medicine have made a breakthrough in ide...according to a report published online today in Na...ify genes (the ,what,) within the genome, it canno...,when, and ,where, gene products are expressed. Ho...

...was thought to be caused by hypoglycemic coma actu...the coma, according to a study in rodents led by r... , The results are surprising, say the authors, a...nt of diabetics in hypoglycemic coma, though they ...rapolated to humans. , Insulin is an essential ...

Other Biology News:Red flag for repetitive stress injuries identified for first time in humans 2 Beyond the DNA: Chemical signatures reveal genetic switches in the genome 2 Glucose triggers brain cell death in rats after hypoglycemic coma 2 Glucose triggers brain cell death in rats after hypoglycemic coma 3

Red flag for repetitive stress injuries identified for first time in humans Beyond the DNA: Chemical signatures reveal genetic switches in the genome Glucose triggers brain cell death in rats after hypoglycemic coma

Canine serum from Equitech-Bio

Rabbit Anti-TOLLIP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.

... W maximum.Constant voltage, constant current, and...ttings and read-outs for precision and reproducibi...g choice for non-IEF ultrathin flatbed gels on Mu...horesis Systems & Standards & Reagents, Power Supp...

Goat Anti-Mouse Nodal Polyclonal Antibody, Unconjugated from R&D Systems

Biology Products:

Canine serum from Equitech-Bio Rabbit Anti-TOLLIP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.EPS 1001 Power Supply from GE Healthcare, formerly Amersham Biosciences Goat Anti-Mouse Nodal Polyclonal Antibody, Unconjugated from R&D Systems

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:3...( NEW YORK Aug. 7 /- Keryx Biopharm...)